steven_gillis

Steven Gillis to join Shire Board of directors

pharmafile | September 19, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shire, Steven Gillis 

Shire has announced that Dr Steven Gillis will join the Board of directors in October this year.

On joining the Board, Gillis will become a member of the Company’s Science & Technology Committee and Remuneration Committee.

Gillis is currently a managing director at ARCH Venture Partners, a provider of venture capital for technology firms, where he is focused on the evaluation of new life science technologies and the development and growth of ARCH’s biotechnology portfolio companies.

Advertisement

Prior to this, Gillis was a founder and director of Corixa Corporation, acquired by GlaxoSmithKline in 2005. Prior to starting Corixa, Gillis was a founder and director of Immunex Corporation.

An immunologist by training, Gillis has authored more than 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is a non-executive director of Genesis Research and Development, a New Zealand and Australian Stock Exchange-listed biotechnology company. He was a non-executive director and then executive chairman and acting president of Trubion Pharmaceuticals, until its sale in 2010.

Shire chairman Matt Emmens, commented:
“Steven’s pioneering and entrepreneurial approach paired with a deep technical and scientific knowledge will complement the existing skills and outlook of the Shire Board. I look forward to him joining in the autumn.”

Related Content

takeda_deerfield_hq

Takeda plans to vacate all 1,000 staff from US HQ by the year’s end

Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, …

novartis_window

Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion

Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

With the completion of Takeda’s £46 billion acquisition of Shire finally done, another even bigger …

The Gateway to Local Adoption Series

Latest content